Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Product › Details

Waters Full Spectrum Molecular Imaging System

Products Next higher product group hybrid Quad-ToF (QTOF) mass spectrometer
Period Status 2015-07-01 sales planned
Organisation Organisation Waters Corporation (NYSE: WAT)
  Group Waters (Group)

Waters Corporation. (3/9/15). "Press Release: Waters Full Spectrum Molecular Imaging System First to Combine Complementary MALDI, DESI and IMS Capabilities". New Orleans, LA.

High-Powered Imaging Techniques on SYNAPT G2-Si Mass Spectrometer Advance Proteomics, Metabolomics, Cell Biology, and Research Pathology and Histology

Waters Corporation (NYSE:WAT) today introduced a new full spectrum molecular imaging system for advanced molecular imaging of tissue samples. Based on the Waters® SYNAPT® G2-Si mass spectrometer, the system is the first ever to allow scientists to access enhanced matrix-assisted laser desorption ionization (MALDI) and desorption electrospray ionization (DESI) with ion mobility separation (IMS) in a single mass spectrometry platform.

The imaging capabilities of this new system enable research laboratories to pinpoint with greater specificity the distribution of large and small molecules within tissue samples. Information derived from imaging experiments can greatly benefit cancer, cardiovascular and neuro-degenerative research by measuring the distribution of molecules in cells and tissues. MS imaging also allows researchers to identify different tissue types based on their molecular composition.

“By combining MALDI with DESI and ion mobility on the same instrument, Waters brings molecular imaging into a new realm,” said Dr. Jeff Mazzeo, Sr. Director, Health Sciences, Waters Division. “We are committed to giving cell biologists, biochemists, clinical researchers and analytical scientists the tools they need to obtain a maximum amount of information to advance their research into human health. The new full spectrum molecular imaging system combines and optimizes Waters' mass spectrometry technologies to deliver a level of detail and molecular information beyond that of any individual imaging technique."

Waters will commence shipments of its full spectrum molecular imaging system in the third quarter of 2015.

About Imaging Mass Spectrometry for Biomedical Science and Clinical Research

The push for more information to unravel the molecular complexities of biological samples is the driving force behind innovation in mass spectrometry imaging for higher spatial and molecular resolution. Mass spectrometry imaging technology, with its ability to discriminate between thousands of different molecular ions simultaneously, can now play a central role by combining traditional tissue analysis with definitive molecular analysis in a number of basic and clinical research settings.

MS imaging is capable of measuring a broad spectrum of endogenous (originating from within) and exogenous (originating from outside) analytes in tissues whether these are proteins, peptides, drugs and their metabolites or lipids. With the “molecular signature” obtained by MS imaging, researchers are better informed regarding the basic, yet complicated, biological pathways which make up cell and tissue functions and drug effects. MS imaging is significantly altering the disease research landscape by providing new insights into the understanding of the mechanisms of cancer, cardiovascular disease and neuro-degenerative diseases.

By virtue of its ability to determine the distribution of drugs molecules and their metabolites, MS imaging is expected to also have a dramatic impact on drug discovery and development.

For More Information

For more information about the Waters full spectrum molecular imaging system, visit

About Waters Corporation (

For more than 50 years, Waters Corporation has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality, consumer products and high-value added chemicals worldwide.

Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.

With revenue of $1.99 billion in 2014, Waters is driving scientific discovery and operational excellence for customers worldwide.


Waters and SYNAPT are trademarks of Waters Corporation.

Brian J. Murphy
Public Relations
+1 508-482-2614

Record changed: 2016-03-19


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for hybrid Quad-ToF (QTOF) mass spectrometer

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group ChinaBio Partnering Forum 2020 Digital Event CBPF2020 650x80

» top